Altria Group Inc Earnings - Q3 2026 Analysis & Highlights
Altria reported Q3 adjusted EPS growth of 4.8%, with results led by Smokeable Products; management also discussed shareholder returns, oral nicotine growth, competition, regulatory developments, and higher full-year EPS guidance.
Key financial results
Adjusted diluted EPS increased 4.8% in Q3 and 5.1% in the first nine months.
Adjusted operating companies income (OCI) in Smokeable Products rose 3.9% to $3.1 billion in Q3 and 4.1% to $8.8 billion year to date.
Oral Tobacco Products adjusted OCI declined 3.7% to $443 million in Q3 and 4% to $1.3 billion for the first nine months.
Altria recorded $191 million of adjusted equity earnings from ABI in Q3, up 21.7% year over year.
Business segment results
Smokeable Products: Adjusted OCI margins were 64.5% in Q3 and 64.8% year to date, up 0.1 and 0.4 percentage points, respectively; price realization was 4.4% in Q3.
Reported domestic cigarette volumes declined 2.9% in Q3 and 2.8% in the first nine months; adjusted for trade inventory movements, Altria estimated declines of 4%, below the estimated 5% industry decline.
Oral Tobacco Products: Adjusted OCI margins were 66.4% in Q3 and 66.8% year to date; reported segment shipment volume fell 4.3% in Q3 and 5.4% for the first nine months, primarily because lower MST volumes outweighed on! growth.
Oral Tobacco Products retail share was 27.9% in Q3 and 28.6% for the first nine months.
Cigars: Reported shipment volume increased 0.9% in Q3 and 2% for the first nine months, with Middleton outperforming the declining large mass-cigar industry.
ABI investment: Management characterized Altria’s ABI stake as a financial investment and said its goal was to maximize its long-term value for shareholders.
Capital allocation
Altria returned more than $6 billion to shareholders in the first nine months, comprising $5.3 billion in dividends and $735 million in share repurchases.
In August, the Board raised the quarterly dividend 4.7% to $1.11 per share; management described this as the company’s 61st increase in 57 years and consistent with its goal of mid-single-digit annual dividend growth.
The Board authorized a $1 billion expansion of the share repurchase program, which now expires on December 31, 2027.
Altria’s debt-to-EBITDA ratio was 1.9 times as of September 30, in line with its target of approximately 2 times.
Industry trends and dynamics
Altria estimated that the oral tobacco category grew 5.5% over the prior six months; in Q3, nicotine pouches gained 5.8 share points and represented more than 60% of the total oral category.
The company said higher nicotine strengths and wider flavor variety were driving nicotine-pouch category growth.
Management said pouch-category growth has been driven substantially by MST consumers switching to pouches, with additional growth from cigarette consumers seeking a reduced-harm nicotine option.
Altria estimated there were approximately 20 million adult vapers at September-end, down 1 million year over year, primarily because fewer e-vapor consumers were using illicit products.
Management said cigarette-category decline rates had moderated, primarily because of lower cross-category movement from illicit e-vapor; it also noted that nicotine demand has historically been more resilient than other consumer packaged goods categories.
Competitive landscape
Altria described the nicotine-pouch category as increasingly competitive, with elevated competitive investment during the quarter.
on! retail share was 8.3% in Q3, up one-tenth of a point year over year but down three-tenths sequentially.
Management said on! PLUS was positioned as a premium proposition and cited NICOSILK pouch technology as a differentiator.
Marlboro held 60% of the premium cigarette segment, up three-tenths of a point year over year and four-tenths sequentially; its overall retail share was flat sequentially and down one point year over year.
The discount cigarette segment gained two share points in Q3 to reach 34.1% of the category; Basic gained 1.8 share points year over year and three-tenths sequentially.
PM USA’s total retail share expanded two-tenths of a point sequentially and three-tenths year over year.
Management said illicit e-vapor products continued to dominate that market, while stepped-up enforcement appeared to be affecting category dynamics and illicit-product supply.
Macroeconomic environment
Management said the overall cost of goods and services had risen roughly 30% since 2021, pressuring household budgets, and that more recent gas-price increases further constrained discretionary income.
Altria described the consumer environment as difficult and said inflation and elevated gas prices continued to pressure consumers.
Management said its data analytics and revenue-growth-management tools helped the company navigate consumer pressure.
Growth opportunities and strategies
PM USA’s total-portfolio approach aims to maximize long-term Smokeable profitability while balancing Marlboro investment and funding growth in smoke-free products.
Cowboy Cut was presented as a premium Marlboro option intended to retain value-sensitive smokers within the Marlboro franchise; management said the brand was in about 100,000 stores, representing roughly 75% of cigarette volume.
Helix expanded on! PLUS 12 mg nationally across Mint, Wintergreen, and Tobacco, introduced Blueberry Mint and Mango Pineapple, and planned a November introduction of Watermelon Mint in select stores.
Helix secured premium retail positioning in stores representing approximately 90% of on! volume and continued investing in brand-building initiatives.
Management said it was continuing to innovate on NJOY ACE and intended to return to the e-vapor market, while taking a disciplined approach focused on competing profitably over time; it did not announce a return date.
Altria continued investing in its smoke-free vision, including on! PLUS and its new higher-strength and flavor offerings.
Financial Guidance and Outlook
Altria raised its 2026 adjusted diluted EPS guidance to $5.66–$5.74, representing growth of 4.5%–6% from the 2025 base of $5.42.
CFO Heather Newman said the higher guidance reflected strong performance through the first nine months and included planned investment in the smoke-free vision, including on! PLUS.
Management said its second-half duty-drawback expectations had not changed and remained balanced between Q3 and Q4; it did not provide a 2027 duty-drawback range.
Management noted that the PMI contract manufacturing agreement would begin in 2027, but did not provide further guidance on its financial impact.
Regulatory environment
Altria said Helix and NJOY filed legal action asking the court to require an FDA review process meeting the statutory 180-day timeframe and to allow products with applications pending beyond that period to remain on the market while a new process is implemented.
After the filing, the FDA announced plans to evaluate changes to the PMTA framework and pursue new rulemaking; Altria said a modernized process should retain rigorous standards while improving clarity, predictability, and efficiency.
Management said a more efficient authorization process must be paired with consistent enforcement against illicit products.
Altria said it welcomed stepped-up federal, state, and local enforcement efforts against illicit e-vapor products, while emphasizing that those efforts needed to be sustained.
